Alexion buying Portola for $18/share

  • "Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care," says Alexion (NASDAQ:ALXN) CEO Ludwig Hantson.
  • The $18 per share all-cash deal is more than double Portola's (NASDAQ:PTLA) close last night of $7.76. It's set to close in Q3.
  • A conference call to discuss is set for 8 ET.

Recommended For You

Comments (41)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.